CliffBio
small molecule

EXBLIFEP

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

Loss of exclusivityNovember 2034latest FDA-listed patent expiry
CompanyOrchid Labs →View the full company profile on CliffBio

Drug detail

Brand nameEXBLIFEP
Active ingredientCEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM
StrengthEQ 2GM BASE/VIAL;0.5GM/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2024
Marketing statusDISCN

Listed patents

PatentExpiresType
11124526November 2034use U-3852
7687488December 2027substance, product

Regulatory exclusivity

CodeExpires
GAINFebruary 2034
NCEFebruary 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EXBLIFEP patent cliff — loss of exclusivity November 2034 | CliffBio